CMC

Essex Bio-Technology Posts Sound 2023 Annual Financial Results, Revenue Up 29.5%, Profit Up 22.1%

Retrieved on: 
Monday, March 18, 2024
Cloud, Research, SKQ1, Quality control, Weather, NMPA, Therapeutic Goods Administration, Environment, Best, Intelligence, Patent, Patient, Conditional sentence, Ophthalmology, Hospital, POCT, Acquisition, CMC, European Medicines Agency, GMP, City, QMS, Bevacizumab, Chemistry, Yoy, US FDA, Traction, Good, Therapy, Point-of-care testing, VISTA, Pharmaceutical industry

The Group weathered the headwinds and managed to deliver sound performances amidst the challenging trading environment in 2023.

Key Points: 
  • The Group weathered the headwinds and managed to deliver sound performances amidst the challenging trading environment in 2023.
  • As of 31 December 2023, the Group had cash and cash equivalents of approximately HK$509.8 million (2022: approximately HK$543.5 million).
  • Together with the interim dividend of HK$0.045 per ordinary share paid on 13 September 2023, the total dividend for 2023 would be HK$0.09 (2022: HK$0.065) per ordinary share.
  • The Group's turnover is primarily made up of the ophthalmology segment ("Ophthalmology") and surgical (wound care and healing) segment ("Surgical").

New Solana Meme Coin to Buy Now for Massive Gains

Retrieved on: 
Tuesday, April 9, 2024
Risk, Research, HUMP, CEX, CMC, Cryptocurrency

The new Solana meme coin is one of the newest trends that has drawn a lot of interest.

Key Points: 
  • The new Solana meme coin is one of the newest trends that has drawn a lot of interest.
  • The cryptocurrency community has taken notice of HUMP, the newest meme coin.
  • Based on the Solana blockchain, which is becoming more and more well-liked in the cryptocurrency world, HUMP is a meme coin.
  • Solana is a great platform for meme coins like HUMP because of its reputation for quick transactions and cheap fees.

The Next Solana Meme Coin ‘HUMP’ Is Set to Shake the Crypto World

Retrieved on: 
Tuesday, April 9, 2024
Risk, Binance, Research, HUMP, CEX, CMC, Cryptocurrency

HUMP is a recent meme coin that is worthwhile to take into account.

Key Points: 
  • HUMP is a recent meme coin that is worthwhile to take into account.
  • The newest meme coin based on the Solana network is called HUMP.
  • To begin with, HUMP is not a copy or rip off of any other meme coin that has been around in the past.
  • HUMP has enormous development potential and is a promising Solana meme coin.

4BIO Capital Portfolio Company Ascend Acquires Florida-Based GMP Manufacturing Capacity

Retrieved on: 
Tuesday, April 9, 2024
Retina, AAV, QC, Partnership, Patient, Research, Acquisition, CMC, Protein, GMP, Investment, Therapy, San Francisco Bay Area, Retinitis pigmentosa, Pharmaceutical industry

London, UK, 9 April 2024 – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm unlocking the treatments of the future by investing in advanced therapies and other emerging technologies, today announces that its portfolio company, Ascend Advanced Therapies (Ascend), an end-to-end gene therapy development partner, has acquired the Contract, Manufacturing and Controls (CMC) team and site in Alachua, Florida, from Beacon Therapeutics (Beacon).

Key Points: 
  • London, UK, 9 April 2024 – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm unlocking the treatments of the future by investing in advanced therapies and other emerging technologies, today announces that its portfolio company, Ascend Advanced Therapies (Ascend), an end-to-end gene therapy development partner, has acquired the Contract, Manufacturing and Controls (CMC) team and site in Alachua, Florida, from Beacon Therapeutics (Beacon).
  • The transaction brings an operational good manufacturing practice (GMP) facility, process and analytical development capabilities, and additional experts to the Ascend team.
  • This key acquisition brings Ascend its first US manufacturing site, a huge milestone for the Company.
  • The facility is highly synergistic to a growing global network of Ascend sites that has been built via critical acquisitions.

North Bay Resources Announces Acquisition of 55.5% of Bishop Gold Mill, California, USA

Retrieved on: 
Monday, April 8, 2024
CMB, Acquisition, CMC, NBRI, Bank statement, OTC

SKIPPACK, Pa., April 08, 2024 (GLOBE NEWSWIRE) -- North Bay Resources Inc. (the “Company” or “North Bay”) (OTC: NBRI) is pleased to announce it has entered into a share purchase agreement to acquire 55.5% of the Bishop Gold Mill, located six miles north of Bishop, Inyo County, California.

Key Points: 
  • SKIPPACK, Pa., April 08, 2024 (GLOBE NEWSWIRE) -- North Bay Resources Inc. (the “Company” or “North Bay”) (OTC: NBRI) is pleased to announce it has entered into a share purchase agreement to acquire 55.5% of the Bishop Gold Mill, located six miles north of Bishop, Inyo County, California.
  • The Company proposes to operate the Bishop Gold Mill in the near to medium term.
  • The mill is currently permitted for operation subject to various conditions and minor infrastructure completions.
  • The annual financial statements and OTC Market annual filing are complete and will be filed upon approvals.

Cielo Announces Closing of Second Tranche of Private Placement of Convertible Debenture Units

Retrieved on: 
Friday, April 5, 2024
Indian stock exchange, Principal, Private, Exchange, Convertible bond, Forced conversion, Issue date, Placement, CMC, Sale, News, Debt, Carbon, Debenture, Convertible, Acceleration, Finance Secretary (India), Calendar, Tranche, NEWS, Conversion, Security (finance)

CALGARY, Alberta, April 05, 2024 (GLOBE NEWSWIRE) -- Cielo Waste Solutions Corp. (TSXV:CMC; OTCQB:CWSFF) (“Cielo” or the “Company”), a renewable fuel company leveraging market ready licensed technology to produce low carbon fuel from wood by-products, is pleased to announce the closing of the second tranche (“Tranche 2”), for gross proceeds of C $1,480,000, of its previously announced non-brokered private placement offering of unsecured convertible debenture units of the Company (collectively, the "Convertible Debenture Units") at a price of C $1,000 per Convertible Debenture Unit for aggregate gross proceeds of up to C $5,000,000 (the "Private Placement"). The Company intends to continue to offer the Convertible Debenture Units on the same terms and close one or more subsequent tranches during the month of April 2024.

Key Points: 
  • CALGARY, Alberta, April 05, 2024 (GLOBE NEWSWIRE) -- Cielo Waste Solutions Corp. (TSXV:CMC; OTCQB:CWSFF) (“Cielo” or the “Company”), a renewable fuel company leveraging market ready licensed technology to produce low carbon fuel from wood by-products, is pleased to announce the closing of the second tranche (“Tranche 2”), for gross proceeds of C $1,480,000, of its previously announced non-brokered private placement offering of unsecured convertible debenture units of the Company (collectively, the "Convertible Debenture Units") at a price of C $1,000 per Convertible Debenture Unit for aggregate gross proceeds of up to C $5,000,000 (the "Private Placement").
  • The Company intends to continue to offer the Convertible Debenture Units on the same terms and close one or more subsequent tranches during the month of April 2024.
  • Pursuant to the closing of Tranche 2, the Company issued 1,480 Convertible Debenture Units for gross proceeds of C $1,480,000, consisting of 1,480 Convertible Debentures and 3,700,000 Warrants.
  • As the Convertible Debentures will be unsecured debt obligations of the Company, each Convertible Debenture will rank subordinate to all secured debt obligations of the Company.

AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, April 4, 2024
Symantec Endpoint Protection, Telephone, CRL, News, NDA, CMC, Migraine, Myenteric plexus, Chemistry, P.C, Therapy, FDA, Food, Pharmaceutical industry

Our investigation concerns whether the board of directors of Axsome have breached their fiduciary duties to the company.

Key Points: 
  • Our investigation concerns whether the board of directors of Axsome have breached their fiduciary duties to the company.
  • Axsome is a biopharmaceutical company that engages in the development of novel therapies for central nervous system disorders in the United States.
  • However, unbeknownst to investors, the Company’s preparation and eventual submission of the AXS-07 NDA was plagued with chemistry, manufacturing, and control (“CMC”) issues.
  • Then, on April 25, 2022, Axsome disclosed in a filing with the U.S. Securities and Exchange Commission that, “[o]n April 22, 2022, Axsome .

TransCode Therapeutics Reports 2023 Results; Provides Business Update

Retrieved on: 
Wednesday, April 3, 2024
Research, Transcoding, Brain, Survival, CFO, TTX, Patient, Operating cost, RNA, Sale, CMC, Cancer, OTS, IND, AACR, Glioblastoma, Pancreatic cancer, Therapy, Genomics, CRISPR, Breast cancer, Melanoma, Debiopharm, FDA, Liver, IRB, Pharmaceutical industry

BOSTON, April 03, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported financial results for 2023 and recent business progress.

Key Points: 
  • BOSTON, April 03, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported financial results for 2023 and recent business progress.
  • “We believe 2023 was extremely productive and pivotal for TransCode.
  • The year was highlighted by preliminary clinical results from our Phase 0 clinical trial with radiolabeled TTX-MC138,” said Tom Fitzgerald, interim CEO and CFO of TransCode.
  • We also continued to achieve other important milestones, with the ultimate objective of fulfilling the promise of RNA therapeutics for oncology applications.

PUSSE Presale Surpasses Expectations - The Platypus on Solana Taking the Meme Coin Market by Storm

Retrieved on: 
Tuesday, April 2, 2024
Environment, Trust, Binance, Policy, CMC, Sensation, Marketing, Cryptocurrency

With its fair launch presale underway and a plethora of exciting features, PUSSE is primed to become Solana's next big meme coin.

Key Points: 
  • With its fair launch presale underway and a plethora of exciting features, PUSSE is primed to become Solana's next big meme coin.
  • PUSSE, the brainchild of a dedicated team of developers and crypto enthusiasts, has received its audit badge from PinkSale, demonstrating its commitment to transparency and security.
  • Embarking on its presale journey on April 1, 2024, PUSSE is backed by a seasoned marketing team, ensuring widespread recognition and adoption.
  • With its compelling features and ambitious vision, PUSSE is poised to redefine success in the meme coin space.

Annovis Bio Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Tuesday, April 2, 2024
Research, Failure, Plasma, KPMG, TDP43, Disease, PD, CSF, Yale University, Patient, Inflammation, Biomarker, CMC, Equity, TAR, Human, European, Drug development, ATM, Safety, Phase, Therapy, Vaccine, Treasury, Syneos Health, Axonal transport, Pharmaceutical industry

MALVERN, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, today provided a summary of corporate updates and reported fourth quarter and full year 2023 financial results.

Key Points: 
  • MALVERN, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, today provided a summary of corporate updates and reported fourth quarter and full year 2023 financial results.
  • For the quarter ended December 31, 2023, Annovis reported a net loss of $22.2 million, compared to a net loss of $7.7 million for the same period in 2022.
  • For the full year ended 2023, Annovis reported a net loss of $56.2 million, compared to a net loss of $25.3 million in 2022.
  • Other income (expense) for the quarter ended December 31, 2023 was ($11.2) million, compared to $0.2 million for the same period in 2022.